Repatha (Evolocumab) in Adolescents Ages 12 to 17: School and Activity Considerations

Why Adolescents With HeFH Are Now on Evolocumab

Familial hypercholesterolemia is more common than most clinicians expect. Heterozygous FH affects roughly 1 in 250 people worldwide, and LDL-C elevation begins at birth in affected individuals. [1] Statins remain first-line therapy, but a meaningful proportion of adolescents with HeFH do not reach guideline-recommended LDL-C targets on maximally tolerated statin doses alone.

The FDA expanded evolocumab's indication to include patients 12 and older in August 2024, based on data from the HAUSER-RCT and its open-label extension. [2] That extension followed participants for 80 weeks and confirmed that LDL-C reductions were maintained without new safety signals specific to the adolescent population. For teenagers already carrying a lifetime of elevated LDL-C exposure, earlier pharmacologic control matters: atherosclerotic plaque can be detectable by carotid intima-media thickness as young as age 11 in untreated HeFH patients. [3]

What the HAUSER-RCT Showed

The HAUSER-RCT enrolled 157 adolescents aged 10 to 17 with HeFH. Participants received evolocumab 420 mg monthly or placebo on top of background lipid-lowering therapy. At 24 weeks, evolocumab produced a 38.3% reduction in LDL-C from baseline compared with a 1.5% increase in the placebo group (P<0.0001). [4] The most commonly reported adverse events were nasopharyngitis, headache, and upper respiratory infection, at rates similar to placebo.

Lifetime Cardiovascular Risk Context

The American Heart Association's 2018 guideline on cholesterol management notes that untreated LDL-C levels above 160 mg/dL in adolescence are associated with measurably increased coronary artery calcium scores in early adulthood. [5] For a 14-year-old with HeFH and a baseline LDL-C of 200 mg/dL, adding evolocumab to a statin could bring LDL-C closer to the <100 mg/dL target endorsed by the American College of Cardiology and AHA for high-risk patients, reducing cumulative plaque burden during the years when tissue is still highly responsive to lipid lowering.

Managing Injections Around the School Day

The practical challenge most families face is not whether evolocumab works. The question is how to fit a biologic injection into a teenager's life without disrupting academics, sports, or social routines. The answer is almost always straightforward because the dosing interval is long.

Choosing an Injection Day That Avoids School

The every-two-week schedule gives families 14 days of flexibility for each dose window. Most prescribing families choose a Friday evening or Saturday morning. That timing means any transient injection-site reaction, mild soreness, or fatigue resolves over the weekend rather than during a school day.

The monthly 420 mg dose (three 140 mg injections given consecutively at a single sitting) takes roughly 10 to 15 minutes to administer. Scheduling it on a Saturday morning gives the teenager the rest of the weekend to recover from any injection-site discomfort, which in the HAUSER-RCT was reported in 5.1% of the evolocumab group vs. 1.3% placebo. [4]

When School-Hour Administration Is Necessary

Some adolescents travel, participate in competitive sports on weekends, or simply miss a home dose. In those cases, the school nurse can administer evolocumab if the following are in place:

1. A signed physician order specifying drug, dose, route, and frequency.
2. A properly labeled, refrigerated medication stored in the nurse's office or a secure cooler.
3. Documented nurse training on the SureClick autoinjector technique (Amgen provides a device training guide through its Repatha patient support line).

Under Section 504 of the Rehabilitation Act, students with chronic conditions requiring medication administration during school hours are entitled to a written health plan. [6] A simple one-page plan that names the medication, dose, injection site, and emergency contact is sufficient for most school districts.

Injection Technique Reminders for Self-Injecting Teens

Adolescents who self-inject should review three points before administering at school or away from home:

• Remove the autoinjector from refrigeration 30 minutes before injection to reduce injection-site stinging.
• Pinch a skin fold at the thigh or abdomen; avoid the waistband area where clothing friction occurs after injection.
• Hold the device firmly against the skin until the yellow indicator fills the window (approximately 15 seconds for the SureClick). [7]

Physical Activity, Sports, and Exercise Safety

No clause in the FDA label for evolocumab restricts physical activity in any age group. Adolescents on evolocumab can and should exercise. Physical activity is itself a cornerstone of cardiovascular risk reduction, and there is no pharmacological basis for limiting it with a PCSK9 inhibitor.

Muscle Symptoms: What Coaches and Athletic Trainers Should Know

Myalgia was reported in approximately 4.4% of pediatric trial participants on evolocumab, compared with 3.2% on placebo, a difference that did not reach statistical significance. [4] any adolescent athlete who reports new or worsening muscle pain, weakness, or dark urine while on evolocumab should be evaluated promptly. The primary concern is not evolocumab itself but rather the possibility of statin-associated myopathy from background therapy, which can be aggravated by intense exercise, dehydration, or heat.

The following four-step framework helps coaches, school nurses, and families triage muscle complaints in evolocumab-treated adolescent athletes:

1. Grade the symptom. Mild soreness confined to worked muscle groups after exercise is typical delayed-onset muscle soreness and does not require intervention.
2. Check the timing. Soreness appearing 48 to 72 hours after a new workout is DOMS. Soreness appearing at rest, or disproportionate to exercise load, warrants a creatine kinase (CK) level.
3. Screen for rhabdomyolysis red flags. Dark or cola-colored urine, severe weakness, and CK above 10 times the upper limit of normal (roughly 2,000 IU/L in adolescents) require emergency evaluation. [8]
4. Do not discontinue evolocumab unilaterally. Stopping a biologic without physician guidance allows LDL-C to rebound to baseline within days. Contact the prescribing cardiologist or lipidologist before any dose change.

Competitive Sports and Injection Timing

Adolescents competing in contact sports (football, wrestling, ice hockey) should avoid injecting into the upper arm on the day of practice or competition. The arm may be grabbed, tackled, or padded in ways that cause mechanical discomfort at a fresh injection site. Thigh or abdominal sites are preferred on game days.

Swimmers and water-polo players should wait at least one hour after injection before getting into chlorinated water, as pool chemicals applied directly to a fresh injection site may cause local irritation. There is no pharmacokinetic reason to avoid swimming after that interval.

Endurance Athletes and Lipid Monitoring

Adolescents engaged in endurance training (cross-country, cycling, rowing) may experience modest transient reductions in HDL-C during heavy training blocks, an expected physiological adaptation. A fasting lipid panel every 3 to 6 months, as recommended by the National Lipid Association for adolescents on PCSK9 inhibitor therapy, allows the treating physician to assess LDL-C response and adjust background statin dosing if needed. [9]

Storage and Travel: Keeping Repatha Cold at School and on Trips

Evolocumab must be stored refrigerated at 36 to 46°F (2 to 8°C). Once removed from refrigeration, it may be kept at room temperature up to 77°F (25°C) for up to 30 days. It must not be frozen and must not be exposed to direct sunlight or heat above 77°F. [7]

School Storage Logistics

Most school nurses' offices have a medication refrigerator. The family should deliver a single injection device (not the whole monthly supply) to the nurse's office only when school-hour administration is planned. Storing the entire month's supply at school is unnecessary and raises security concerns.

A FRIO cooling wallet, available without prescription, can keep a single autoinjector at safe temperatures for up to 45 hours using only water activation. These are practical for field trips, overnight competitions, or travel days when refrigeration is uncertain.

Travel Across Time Zones

Time zone changes do not affect evolocumab dosing in a clinically meaningful way because the dosing interval is measured in weeks, not hours. A teenager flying from New York to London for a school trip can simply shift the injection day by one or two calendar days without any effect on drug efficacy. The half-life of evolocumab is approximately 11 to 17 days, meaning a 48-hour delay produces negligible change in plasma drug concentration. [10]

International travel does require planning around customs and airport security:

• Carry a physician's letter identifying the medication, the diagnosis, and the needle device.
• Transport the autoinjector in carry-on luggage, never in checked baggage (temperature fluctuations in cargo holds may exceed safe ranges).
• TSA permits medically necessary injectable medications and their supplies through security checkpoints with proper documentation. [11]

Talking to the School: What Parents and Teens Should Disclose

Adolescents are not obligated to disclose their diagnosis to teachers, coaches, or classmates. Familial hypercholesterolemia carries no stigma, but teenagers generally prefer privacy. The minimum necessary disclosure is to the school nurse and, if relevant, the athletic trainer.

Communicating With the Athletic Trainer

A brief conversation covering three points is usually enough. First, the student takes a biologic injection every two weeks for a hereditary cholesterol condition. Second, there are no activity restrictions, but muscle aches that seem out of proportion to exercise should be reported. Third, the student carries the prescribing physician's contact number.

Written documentation from the physician strengthens this conversation. A one-paragraph letter stating "this patient has no exercise restrictions and may participate fully in all school athletic activities" prevents the athletic trainer from benching the student out of misplaced caution.

Peer Situations and Social Context

Self-consciousness about injections is real for teenagers. The every-two-week schedule means most adolescents inject at home and never need to do so at school at all. For those who do inject at school, the nurse's office provides privacy. The student does not need to explain anything to friends.

The Familial Hypercholesterolaemia Studies Collaboration (FHSC) has documented that disease awareness and adherence are closely linked in adolescents: teens who understand their condition and its treatment rationale show significantly higher medication persistence rates than those who were simply told to take a drug. [12] A 15-minute shared decision-making conversation with the prescribing physician, tailored to the adolescent rather than only the parents, is associated with better 12-month adherence in pediatric lipid clinics.

Adherence Strategies Specific to Adolescent Schedules

Adherence to biologic therapy in teenagers deserves special attention. A 2022 analysis of pediatric statin adherence published in the Journal of the American College of Cardiology found that adherence rates among adolescents with FH dropped to approximately 57% by 12 months without structured support. [13] PCSK9 inhibitor adherence data in adolescents are still emerging, but the pattern is likely similar.

Anchoring Injections to Existing Habits

Pairing the injection day with a recurring event (Friday movie night, Saturday morning practice, a monthly family dinner) creates a behavioral anchor that is more reliable than calendar reminders alone. Amgen's Repatha Connect patient support program offers dose reminder calls and text messages, which may help adolescents who prefer digital reminders. [7]

Parent Involvement Without Undermining Autonomy

Parents who administer injections for 12- and 13-year-olds should have a transition plan toward self-injection by age 14 to 15. Research in pediatric chronic disease management consistently shows that adolescents who take ownership of their own treatment administration report higher satisfaction and better adherence than those who remain dependent on parental administration into mid-adolescence. [14]

A supervised practice session with the SureClick autoinjector using the provided training device (a needle-free simulator included with the starter kit) gives the teenager hands-on confidence before the first live injection.

Monitoring Lab Visits During the School Year

Fasting lipid panels require a morning blood draw after at least 9 to 12 hours of fasting. Scheduling these on school days means the adolescent either misses morning classes or fasts through breakfast, which is new. Booking the lab visit for the first Saturday of each monitoring quarter avoids both problems. The prescriber should clarify whether fasting is strictly required (it is for the most accurate LDL-C and triglyceride values) or whether a non-fasting panel is acceptable for routine monitoring.

Side Effects Relevant to the School and Athletic Environment

The overall safety profile of evolocumab in adolescents mirrors the adult profile, which is favorable. The most commonly reported adverse events in the HAUSER-RCT were nasopharyngitis (17.9% evolocumab vs. 17.1% placebo), headache (10.3% vs. 6.6%), and upper respiratory infection (7.7% vs. 5.3%). [4] None of these are specific to evolocumab pharmacology; they reflect the background rate of illness in a school-age population.

Injection-Site Reactions

Injection-site reactions occurred in 5.1% of evolocumab-treated adolescents vs. 1.3% in placebo. These are typically redness, mild swelling, or bruising lasting 24 to 48 hours. They do not require treatment beyond cool compress application and do not affect activity.

Students who develop a visible injection-site reaction on the upper arm the day after a dose should inform their gym teacher or athletic trainer, not because the reaction is dangerous, but so it is not misidentified as a bruise from a sports injury.

Neurocognitive Considerations

Adult trials raised early theoretical questions about PCSK9 inhibition and neurocognitive function due to very low achieved LDL-C levels. The EBBINGHAUS trial (N=1,204) found no difference in neurocognitive function between evolocumab and placebo groups over 19 months of follow-up. [15] No pediatric trial has identified a school-performance signal. Adolescents, parents, and school counselors can be reassured that the drug is not expected to affect concentration, memory, or academic performance.